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OBJECTIVES: To quantify the potential impact of PCV7 on
rates of acute otitis media-related ambulatory visits and antibi-
otic prescriptions in children aged <2 years enrolled in private
insurance plans. METHODS: We performed a retrospective
cohort study of the 1997–2004 MarketScan databases. Analysis
included more than 500,000 person-years of observations for
children aged <2 years. Trends in rates of ICD-9 coded ambula-
tory visits and antibiotic prescriptions due to acute otitis media
were evaluated and the national direct medical expenditures for
these outcomes in young children were estimated. RESULTS:
Comparing 2004 to the baseline period 1997–1999, before
vaccine introduction, rates of ambulatory visits and antibiotic
prescriptions due to acute otitis media declined from 2173 to
1244 per 1000 person-years (42.7%, P < 0.001) and from 1237
to 721 per 1000 (41.7% P < 0.001), respectively. Total estimated
national direct medical expenditures for acute otitis media-
related ambulatory visits and antibiotic prescriptions in young
children declined from an average of $1.40 billion during
1997–1999 to $0.95 billion in 2004 (32.2%). CONCLUSION:
Following PCV7 introduction, acute otitis media-related ambu-
latory visits and associated antibiotic prescriptions in children
aged < 2 years declined more than expected on the basis of pre-
licensure clinical trials. Although other factors such as the ratio-
nal antibiotic use guidelines may have contributed to the trend,
our results suggest that PCV7 may play an important role in
reducing the burden of acute otitis media resulting in a major
savings in medical care cost.
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OBJECTIVES: Using intraocular pressure lowering agents
(IOPLAs) is the major treatment approach for glaucoma.
Prostaglandin analogs (PAs) are commonly used as ﬁrst-line
treatment; Patients on PAs may receive other IOPLAs as adjunc-
tive therapy (AT). Treatment of systemic hypertension with oral
antihypertensives (AHs) may affect intraocular pressure. We
quantiﬁed the use of AT and AH in association with PAs.
METHODS: We conducted a cohort study using claims data
from Québec, Canada. We identiﬁed all patients with a ﬁrst
claim for PAs (bimatoprost, latanoprost or travoprost) between
05-24-03 and 02-28-05. AT and AH utilization were identiﬁed
by at least two claims in the 12-month follow-up period from
their ﬁrst PA prescription. Statistical and descriptive analyses
were performed using SAS 9.1. RESULTS: We included 10,618
patients (average age = 74 ± 10, 60% females). PA users naïve
to IOPLA treatment comprised 60% of the cohort. Of that
cohort, we identiﬁed 3813 patients who were not on statin
therapy. Of those 3813 patients, 1135 were on PA only, 706 were
on PA+AT, 1291 were on PA+AH, and 681 were on PA+AT+AH.
Of the PA and non-AH users, 38% were on AT, and of the
PA+AH users, 35% were on AT. There were signiﬁcant differ-
ences among these groups (χ2 = 5.988, p = 0.014). The time to
adjunct therapy for the PA+AT users was 165 days for the non-
AH and 198 days for the AH groups, respectively, with statisti-
cally signiﬁcance differences (Kruskal-Wallis Test, χ2 = 14.93, 
p < 0.001). It was also determined that the PA+AT+AH users
were signiﬁcantly older than the PA+AT users (Kruskal-Wallis
Test, χ2 = 101.47, p < 0.001). CONCLUSION: Patients on PA
using AHs required less AT therapy in the ﬁrst 12 months of PA
use, and started AT later than non-AH users. Further research is
warranted for incident vs. prevalent analyses, to fully evaluate
the impact of AH therapy on the ability to control IOP.
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